<DOC>
	<DOC>NCT03022851</DOC>
	<brief_summary>This study aims to investigate safety and efficacy of Occlutech® AFR device in patients with severe pulmonary hypertension (PH).</brief_summary>
	<brief_title>The Prophet Trial - Pilot Study to Assess Safety and Efficacy of a Novel Atrial Flow Regulator (AFR) in Patients With Pulmonary Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension, Pulmonary</mesh_term>
	<criteria>Age is ≥ 6 years. Patient consents to participation Patient agrees to comply with the followup schedule Right heart failure, chronic and clinically severe Syncope due to acute Pulmonary Hypertension episodes Severe pulmonary hypertension as evident by echocardiography or catheterisation Patient has had a successful ballon atrial septostomy (BAS) procedure and is in a stable hemodynamic state, as assessed by the investigator Local or generalized sepsis or other acute infection(s) Thrombophilic coagulation disorder Allergy to nickel and/or titanium and/or nickel/titaniumbased materials Allergy to antiplatelet, coagulant, or thrombotic therapy Intolerance to contrast agents Participation in other medical trials shorter than 30 days before the intended AFR implantation procedure Pregnancy (assessed in patients with child bearing potential by urine dip stick) Occluded inferior vena cava access Previous Atrial septum defect (ASD)/ Patent Foramen Ovale (PFO) closure device in place Intracardiac thrombus</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>